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Clinical PerspectiveWhat Is New?In patients with severe hyperkalemia resulting from a critical medical condition, the presence of a Brugada syndrome ECG phenotype is associated with a high prevalence of malignant arrhythmias and all‐cause mortality.Higher serum potassium levels and male sex are independent predictors for the presence of a Brugada ECG phenotype.Modeling studies indicate that the Brugada ECG phenotype induced by severe hyperkalemia occurs secondary to membrane depolarization and consequent reduced sodium channel availability, resulting in delayed and heterogeneous conduction, particularly in the presence of fibrosis at the right ventricular outflow tract.What Are the Clinical Implications?Prompt recognition of this clinical‐morphological entity and immediate treatment of hyperkalemia and surveillance of potential life‐threatening arrhythmias is strongly recommended.Drug‐provocation testing following normalization of serum potassium levels may be considered to uncover underlying Brugada syndrome.

Introduction {#jah33801-sec-0008}
============

Brugada syndrome (BrS) is characterized by distinctive ST‐segment elevation in the right precordial leads of the ECG, and propensity for sudden cardiac death.[1](#jah33801-bib-0001){ref-type="ref"}, [2](#jah33801-bib-0002){ref-type="ref"} According to the 2013 consensus statement on cardiac arrhythmia syndromes and the 2016 J‐Wave syndromes expert consensus conference report, BrS is diagnosed in patients with spontaneous ST‐segment elevation (≥2 mm) with type 1 morphology in ≥1 precordial leads, particularly V1 and V2, positioned on the second and third or fourth intercostal spaces.[3](#jah33801-bib-0003){ref-type="ref"}, [4](#jah33801-bib-0004){ref-type="ref"} BrS has been considered as a primary electric cardiac disease caused by mutations in genes coding sodium, calcium, and potassium channels in ≈30% of patients.[3](#jah33801-bib-0003){ref-type="ref"}, [4](#jah33801-bib-0004){ref-type="ref"}, [5](#jah33801-bib-0005){ref-type="ref"} However, other studies found no clear genetic association, and minor structural abnormalities were associated with the syndrome.[6](#jah33801-bib-0006){ref-type="ref"}, [7](#jah33801-bib-0007){ref-type="ref"}, [8](#jah33801-bib-0008){ref-type="ref"} Moreover, some environmental factors can induce ECG morphologies similar or identical to BrS in the absence of genetic mutations or ion‐channel dysfunction.[6](#jah33801-bib-0006){ref-type="ref"}, [9](#jah33801-bib-0009){ref-type="ref"} The acquired form of Brugada‐like ECG pattern, also called Brugada phenotype (BrPh), is manifested by a Brugada ECG pattern in the presence of an identifiable underlying condition and typically disappears after its resolution.[3](#jah33801-bib-0003){ref-type="ref"}, [4](#jah33801-bib-0004){ref-type="ref"}, [10](#jah33801-bib-0010){ref-type="ref"}, [11](#jah33801-bib-0011){ref-type="ref"}, [12](#jah33801-bib-0012){ref-type="ref"} Multiple metabolic conditions can lead to BrPh ECG; the majority of cases are associated with serum K^+^ abnormalities, hyperkalemia being the most frequent single cause.[10](#jah33801-bib-0010){ref-type="ref"} Although classical hyperkalemia produces several well‐described ECG alterations, only a minority of patients develop BrPh.[10](#jah33801-bib-0010){ref-type="ref"}, [12](#jah33801-bib-0012){ref-type="ref"} Nevertheless, the clinical characteristics and prognostic impact on patients developing BrPh are poorly known.

The main mechanism responsible for BrS phenotype relate to abnormal patterns of repolarization and/or impulse activation at the right ventricular outflow tract (RVOT).[13](#jah33801-bib-0013){ref-type="ref"}, [14](#jah33801-bib-0014){ref-type="ref"}, [15](#jah33801-bib-0015){ref-type="ref"}, [16](#jah33801-bib-0016){ref-type="ref"} However, whether BrPh represents transient alterations in myocardial depolarization, repolarization, or any other mechanism is yet to be elucidated. Moreover, the transient nature of BrPh casts doubt about its genetic origin or relation to structural abnormalities, or both.

The objectives of the study were several fold, including to: (1) describe the clinical and ECG characteristics and clinical outcome of patients with hyperkalemic BrPh; (2) compare the clinical characteristics of patients with hyperkalemic BrPh with those of patients with severe hyperkalemia but no BrPh ECG; (3) conduct computer simulations in a three‐dimensional model of ventricular propagation under conditions of varying hyperkalemia to analyze the implication of mutations and/or structural abnormalities in relation to the Brugada sign[17](#jah33801-bib-0017){ref-type="ref"}; (4) study the mechanisms underlying hyperkalemic BrPh; and (5) evaluate the proarrhythmic risk of BrPh in the presence of hyperkalemia.

Methods {#jah33801-sec-0009}
=======

Data, analytical methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The data will be made available for requests made to corresponding author by e‐mail.

Patients {#jah33801-sec-0010}
--------

From 2010 to 2016, we prospectively identified patients hospitalized at our institution who presented an ECG suggestive of BrS in the context of severe hyperkalemia (group 1). Inclusion in this series required moderate‐to‐severe hyperkalemia (serum potassium \[K^+^\] ≥6.5 mmol/L), hospitalization for an acute illness and type 1 or 2 Brugada ECG pattern on right precordial leads V1 to V2, which normalized after serum K^+^ levels returned to reference values.[10](#jah33801-bib-0010){ref-type="ref"} Additionally, we also considered patients with atypical ST‐segment elevation on the right precordial leads without BrS and/or aVR sign.[18](#jah33801-bib-0018){ref-type="ref"}, [19](#jah33801-bib-0019){ref-type="ref"} Furthermore, we retrospectively reviewed the charts of all adults admitted to our center during 2013 who developed severe hyperkalemia any time during admission, with an available ECG recording at peak serum K^+^ ≥6.5 mmol/L (group 2).

For all patients, we recorded demographic and clinical characteristics, laboratory data, treatments, and hospital outcomes, including diagnosis at discharge and survival status. The ECGs obtained during peak serum K^+^ were analyzed for rate, rhythm, *P*‐wave voltage, PR interval duration, QRS width, QRS axis, QTc interval, maximum height of ST‐segment elevation, and T wave height. In group 1 patients, the recorded ECGs were compared before and after treatment of hyperkalemia. In group 1 patients displaying a BrPh ECG, a provocative flecainide test was performed after normalization of the electrolyte disturbances. Patients were considered to be at a low clinical probability of having BrS if they had a negative flecainide challenge test, a lack of family history of syncope or sudden death, no previous history of syncope or cardiac arrhythmia, and normal body temperature.[10](#jah33801-bib-0010){ref-type="ref"} The institutional review board of our center waived the informed consent form and approved the study.

Computer Simulations {#jah33801-sec-0011}
--------------------

A multiscale computer model was constructed to determine conditions for the BrPh ECG in patients with hyperkalemia. The model was based on several parameters, including electrophysiological dynamics, transmural differences in cell type, fiber orientation, and fibrosis at varying extracellular potassium concentrations (\[K+\]o) ranging between 5.4 and 10.5 mmol/L. A human wedge model of the anterior ventricular wall, including both ventricles and the RVOT, was created using a reference geometry (normal young male), available for the ECGSIM software.[20](#jah33801-bib-0020){ref-type="ref"} The mesh contained 281 191 nodes and 1 460 832 elements with a mean edge length of 290.8±296.6 μm. Human ventricular cell dynamics and action potential morphologies of cell types were simulated using the O\'Hara--Rudy model,[21](#jah33801-bib-0021){ref-type="ref"} with modifications in the sodium current suggested by Dutta et al,[22](#jah33801-bib-0022){ref-type="ref"} which enabled realistic simulations under hyperkalemic conditions. Ventricular activation sequences were based on Cardone‐Noott et al,[23](#jah33801-bib-0023){ref-type="ref"} being initiated in 3 areas in our model. Anisotropic conduction attributed to fiber orientation changes was incorporated into the model using an anisotropy ratio of 10:1, D\|\|:D⊥, where D\|\| and D⊥ are the longitudinal and transverse diffusion coefficients, respectively. Therefore, propagation in any direction of the three‐dimensional model depended on fiber direction. The RVOT diffusion coefficient was 25% of either ventricle, keeping the same anisotropy ratio.

Simulations were performed under 4 different conditions: (1) healthy RVOT; (2) fibrotic RVOT; (3) RVOT with a gradient of transient outward potassium current (I~to~); and (4) fibrotic RVOT with an epi‐ to endocardium I~to~ gradient. Various \[K^+^\]~o~ concentrations (5.4, 7.5, 10.0, and 10.5 mmol/L) were chosen considering that the level of serum K^+^ registered in patients could be lower than in the extracellular space.[24](#jah33801-bib-0024){ref-type="ref"} Different \[K^+^\]~o~ were tested in basal conditions and RVOT with 65% of fibrotic tissue. Fibrotic tissue was modeled by randomly disconnecting a specific percentage of available nodes in the RVOT. The enhanced I~to~ conductance gradient was established by increasing the maximal conductance of the current on the epicardium of the RVOT, from its basal level (0.08 mS/μF) to 0.30, 0.70, and 1.50 mS/μF; these values were consistent with experimentally derived data related to BrS.[25](#jah33801-bib-0025){ref-type="ref"} Different cases were tested, combining the amount of fibrosis (55, 65, and 75%), \[K^+^\]~o~ concentrations (5.4 and 10.5 mmol/L), and increasing I~to~ conductance gradient from baseline to the maximal conductance, 1.50 mS/μF. Monodomain equations were solved using the Forward‐Euler algorithm with a fixed time step of 0.01 ms on a graphic processors unit (GPU Tesla K20 5GRAM DDR5).[26](#jah33801-bib-0026){ref-type="ref"} Three virtual electrodes were positioned at standard electrode locations for the calculation of pseudo‐ECGs V1, V2, and V3.

Statistical Analyses {#jah33801-sec-0012}
--------------------

Categorical variables are reported as number and percentage and were compared using Fisher\'s exact test or the chi‐square test, as appropriate. For continuous variables, normal distribution was assessed by the Kolmogorov--Smirnov test and are reported as mean±SD or median and interquartile range, depending on whether they were normally or non‐normally distributed. Continuous variables comparisons were made using the Student *t* test or nonparametric tests, as appropriate. Multiple logistic regression analysis was performed to identify predictors of a BrPh ECG in patients with severe hyperkalemia. Analyses were performed using SPSS software (version 22; SPSS, Inc, Chicago, IL), and statistical significance was established at *P*\<0.05.

Results {#jah33801-sec-0013}
=======

Clinical Characteristics and Outcome of Patients With Hyperkalemic BrPh {#jah33801-sec-0014}
-----------------------------------------------------------------------

During a 6‐year observation period, we identified 15 patients with severe hyperkalemia and type 1 or 2 ECG Brugada pattern or atypical repolarization signs on the right precordial leads (ST‐segment elevation on the right precordial leads pattern).[3](#jah33801-bib-0003){ref-type="ref"}, [4](#jah33801-bib-0004){ref-type="ref"}, [18](#jah33801-bib-0018){ref-type="ref"} Figure [1](#jah33801-fig-0001){ref-type="fig"} shows ECG data from precordial lead recordings from each patient displaying a BrPh ECG at the time of peak hyperkalemia. None of the patients had a family history of BrS, cardiac arrhythmias, or syncope. Baseline clinical characteristics, hospital admission reason, and etiology of hyperkalemia are shown in Table [1](#jah33801-tbl-0001){ref-type="table"}. In all cases, ECG changes were transient and disappeared after plasma serum K^+^ levels returned to normal (Table [2](#jah33801-tbl-0002){ref-type="table"}).

![ECG recordings of patients displaying brugada ECG pattern at the time of peak hyperkalemia (precordial and aVR leads).](JAH3-8-e010115-g001){#jah33801-fig-0001}

###### 

Clinical Characteristics and Outcome of Patients With Brugada Phenotype

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pt   Sex   Age, y   K^+^ (mmol/L)   Hospital Admission Reason       Hyperkalemia Etiology            Flecainide Test                              Diagnosis                                       Outcome
  ---- ----- -------- --------------- ------------------------------- -------------------------------- -------------------------------------------- ----------------------------------------------- ---------------------------------
  1    F     62       8.2             OH SCD                          Potassium supplements overdose   No                                           Suicide                                         Death

  2    M     89       7.4             Diarrhea dehydration            CKD descompensation              No[\*](#jah33801-note-0004){ref-type="fn"}   Gastrointestinal infection                      Alive

  3    M     45       7.7             Decompensated liver cirrhosis   AKD                              No                                           Terminal liver disease                          Death, 3 months after discharge

  4    M     53       6.9             DKA                             AKD                              Yes                                          DKA, BrS                                        Alive

  5    F     83       9.1             OH SCD                          ≥2 RAAS inhibitors               No                                           Hyperkalemia                                    Death

  6    M     63       8.6             Sepsis                          AKD\                             No                                           Bilateral pneumonia                             Death
                                                                      Espironolactone                                                                                                               

  7    M     41       7.7             OH SCD                          AKD                              No                                           Benzodiazepine overdose                         Death

  8    M     38       7.2             Dehydration                     AKD                              Yes                                          Gastrointestinal infection                      Alive

  9    F     57       8.6             Sepsis                          AKD                              No                                           Urinary tract infectionadvanced breast cancer   Death

  10   M     61       6.8             Lung cancer surgery             IV fluid overdose                Yes                                          Lung cancer                                     Alive

  11   M     78       8.5             Diarrhea dehydration            AKD                              Yes                                          Gastrointestinal infection                      Alive

  12   M     54       7.5             Acute renal disease             AKD                              No[\*](#jah33801-note-0004){ref-type="fn"}   Gastrointestinal infection                      Alive

  13   M     35       8.1             Abdominal cancer                AKD                              No                                           Metastatic testicular cancer                    Death

  14   M     41       8.6             Sepsis                          CKD                              No[\*](#jah33801-note-0004){ref-type="fn"}   Sepsis                                          Alive

  15   M     46       7.7             DKA                             AKD                              Yes                                          DKA                                             Alive
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

≥2 RAAS inhibitors indicates combination of ≥2 ACE inhibitor, angiotensin II--receptor blocker, aldosterone antagonist, or renin inhibitors; AKD, acute kidney disease; BrS, Brugada syndrome; CKD, chronic kidney disease; DKA, diabetic ketoacidosis; OH SCD, out‐of‐hospital sudden cardiac death.

Flecainide test not performed because of clinical reasons or living overseas.

###### 

Electrocardiographic Characteristics at Peak K^+^ Levels and Following K^+^ Levels Normalization in Patients Displaying a Brugada ECG Pattern Recording

                                       ECG at Peak Hyperkalemia Brugada Phenotype (n=15)   ECG After K levels Normalization (n=15)   *P* Value
  ------------------------------------ --------------------------------------------------- ----------------------------------------- -----------
  Heart rate, bpm, median (IQR)        89 (26)                                             60 (60--89)                               0.08
  *P*‐wave voltage, mm, median (IQR)   0.5 (0.5--1)                                        1 (0.5--1.3)                              0.13
  PR segment, ms, median (IQR)         160 (160--220)                                      160 (130--190)                            0.27
  QRS abnormal axis, n (%)             9 (60)                                              2 (16)                                    0.04
  QRS width, ms, median (IQR)          120 (110--160)                                      80 (80--120)                              0.001
  QTc segment, ms, median (IQR)        433 (69)                                            420 (395--430)                            0.58
  T wave height, mm, median (IQR)      7 (5--14)                                           3 (3--6)                                  0.002

IQR indicates interquartile range; K, potassium.

Most patients were middle aged (56.4±16 years old) men (79%), presenting a critically ill state on admission. In fact, 3 were brought to the emergency room because of out‐of‐hospital sudden cardiac arrest. The most frequent primary etiology of hyperkalemia was decompensated renal function. Six (43%) patients died during admission for different reasons (Table [1](#jah33801-tbl-0001){ref-type="table"}): Two patients presented postanoxic encephalopathy, 1 had recurrent cardiac arrest at the time of arrival in the emergency room, and 2 presented septic shock (patients 6 and 9). One patient died after prolonged admission because of metastatic testicular cancer. Patient 3 died 3 months after hospital discharge because of terminal hepatic disease.

We contacted 8 of the surviving patients, and a flecainide test was finally performed in 5 (of the other 3, 1 was dismissed because of severe neurologic chronic sequelae and 2 lived overseas). The flecainide test was negative in 4 patients and positive in 1. Patient 4 was a 53‐year‐old male admitted for diabetic ketoacidosis with hyperkalemia (K^+^, 6.9 mmol/L; serum pH, 6.89). He presented a BrPh pattern on admission (Figure [2](#jah33801-fig-0002){ref-type="fig"}A), which was normalized after correction of the serum K^+^ (4.5 mmol/L; serum pH, 7.1; Figure [2](#jah33801-fig-0002){ref-type="fig"}B). Several weeks after hospital discharge, while the patient was clinically stable, a flecainide test (2‐mg/kg intravenous infusion over 10 minutes) uncovered a type 1 Brugada pattern (Figure [2](#jah33801-fig-0002){ref-type="fig"}C).

![Brugada pattern uncovered by hyperkalemia in a patient with Brugada syndrome. **A**, Patient previously asymptomatic, admitted because of diabetic ketoacidosis, displaying an ECG Brugada pattern. **B**, ECG normalized after correction of the electrolyte disturbances. **C**, Baseline ECG and following infusion of Flecainide.](JAH3-8-e010115-g002){#jah33801-fig-0002}

Clinical Characteristics and Outcome of Patients With Hyperkalemic BrPh Versus Severe Hyperkalemia With Non‐BrPh Pattern {#jah33801-sec-0015}
------------------------------------------------------------------------------------------------------------------------

During 2013, 245 patients presented severe hyperkalemia of 46 459 admitted to our institution (0.53%). Of those, 44 (18%) had an ECG recording available at the time of peak hyperkalemia. Table [3](#jah33801-tbl-0003){ref-type="table"} shows baseline characteristics of BrPh patients (group 1) and severe hyperkalemic patients without BrPh (group 2). Compared with group 2 patients, BrPh patients were younger and had higher serum K^+^ values (1 mmol/L higher on average), lower pH, and less chronic kidney disease; hypertension tended to be less prevalent and so was the use of angiotensin‐receptor blockers. On ECG, BrPh hyperkalemic patients showed wider QRS, and frequently presented abnormal QRS axis and greater T‐wave height compared with non‐BrPh hyperkalemic patients (Table [3](#jah33801-tbl-0003){ref-type="table"}). Multivariate analysis revealed that higher serum K^+^ levels (odds ratio, 15.8; 95% CI, 3.1--79; *P*=0.001) and male sex (odds ratio, 17; 95% CI, 1.05--286; *P*=0.045) were independent predictors for developing BrPh ECG in patients with severe hyperkalemia. Moreover, lower arterial pH, available in a smaller number of patient samples, was also related to development of BrPh ECG (Tables [3](#jah33801-tbl-0003){ref-type="table"} and [4](#jah33801-tbl-0004){ref-type="table"}).

###### 

Clinical Characteristics in Patients With (Group 1) Versus Without Brugada Phenotype Pattern (Group 2) in the Presence of Severe Hyperkalemia

  Clinical Characteristics and Outcome                                  Group 1 Hyperkalemic Brugada Phenotype (n=15)   Group 2 Hyperkalemic Non‐Brugada Phenotype (n=44)   *P* Value
  --------------------------------------------------------------------- ----------------------------------------------- --------------------------------------------------- -----------
  Age, y, median (IQR)                                                  54 (41--62)                                     74 (60--83)                                         0.002
  Female, n (%)                                                         3 (20)                                          20 (46)                                             0.08
  Hypertension, n (%)                                                   7 (47)                                          31 (71)                                             0.06
  Diabetes mellitus, n (%)                                              7 (47)                                          20 (45)                                             0.94
  CKD, n (%)                                                            3 (20)                                          23 (52)                                             0.04
  Smoking, n (%)                                                        4 (27)                                          12 (27)                                             0.92
  Cardiac disease, n (%)                                                5 (33)                                          26 (59)                                             0.12
  COPD, n (%)                                                           1 (7)                                           11 (25)                                             0.15
  BB, n (%)                                                             3 (20)                                          17 (39)                                             0.19
  ACE inhibitor, n (%)                                                  5 (33)                                          9 (21)                                              0.53
  ARB, n (%)                                                            0                                               8 (18)                                              0.09
  Mineralocorticoid antagonist, n (%)                                   3 (20)                                          6 (14)                                              0.48
  Glycemia, mmol/L, median (IQR)                                        144 (101--272)                                  131 (105--185)                                      0.52
  Crp, mg/dL, median (IQR)                                              3.2 (1.7--12.4)                                 2.5 (1.5--3.8)                                      0.31
  (K), mmol/L, median (IQR)                                             7.7 (7.4--8.6)                                  6.9 (6.6--7.2)                                      \<0.001
  Serum sodium, mmol/L, median (IQR)                                    132 (115--136)                                  133 (130--136)                                      0.12
  Serum pH, median (IQR)[\*](#jah33801-note-0007){ref-type="fn"}        7.07 (6.9--7.2)                                 7.25 (7.2--7.3)                                     0.003
  HCO~3~, mEq/L, median (IQR)[\*](#jah33801-note-0007){ref-type="fn"}   16 (5--20)                                      20 (15--27)                                         0.03
  LVEF\<60%, n (%)                                                      0                                               11 (36)                                             0.03
  Exitus, n (%)                                                         6 (40)                                          18 (43)                                             0.85

ACE inhibitor indicates angiotensin‐converting‐enzyme use; ARB, angiotensin‐receptor blocker use; BB, betablocking agent; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; IQR, interquartile range; LVEF, left ventricular ejection fraction.

Available in 49 patients.

###### 

Electrocardiographic Characteristics in Patients With Versus Without Brugada Phenotype Pattern

                                       Group 1 Hyperkalemic Brugada Phenotype (n=15)   Group 2 Hyperkalemic Non‐Brugada Phenotype (n=44)   *P* Value
  ------------------------------------ ----------------------------------------------- --------------------------------------------------- -----------
  Heart rate, bpm, median (IQR)        87 (75--115)                                    80 (63--99)                                         0.20
  *P*‐wave voltage, mm, median (IQR)   0.5 (0.4--1.3)                                  0.5 (0.5--1.0)                                      0.67
  PR segment, ms, median (IQR)         160 (160--210)                                  160 (120--180)                                      0.32
  QRS abnormal axis, n (%)             8 (57.1)                                        17 (38.6)                                           0.01
  QRS width, ms, median (IQR)          130 (110--160)                                  100 (80--120)                                       0.03
  QTc segment, ms, median (IQR)        425 (368--475)                                  415 (390--450)                                      0.68
  T‐wave height, mm, median (IQR)      7.5 (5.4--14.5)                                 4 (2.5--6.0)                                        0.001

IQR indicates interquartile range.

Of 15 patients with BrPh, 6 (40%) had malignant arrhythmias (3 presented as sudden cardiac arrest): 4 had ventricular tachycardia, 1 ventricular fibrillation, and 1 high‐degree atrioventricular block. In group 2, 11 patients (25%) had malignant arrhythmias: 7 high‐degree atrioventricular block, 3 ventricular tachycardia, and 1 ventricular fibrillation. Thus, patients with BrPh had a higher likelihood of developing malignant arrhythmias. Nevertheless, total in‐hospital mortality was similar (*P*\<0.9) in both groups: 6 patients in group 1 (43%) versus 18 patients in group 2 (41%).

Hyperkalemia, Fibrosis, and the Mechanism of BrPh {#jah33801-sec-0016}
-------------------------------------------------

To differentiate between the mechanisms underlying BrPh versus non‐Brugada ECGs during hyperkalemia, we simulated the effects of increasing \[K^+^\]~o~ in a human wedge model of the anterior ventricular walls, including the RVOT. Elevating the \[K^+^\]~o~ reduced the resting membrane potential throughout from −87.9±0.1 mV at \[K^+^\]~o~=5.4 mmol/L to −69.93±0.08 mV at \[K^+^\]~o~=10.5 mmol/L, regardless of whether or not the RVOT was fibrotic. As expected, the depolarized resting potential reduced the availability of the sodium channels and slowed the conduction velocity (CV). Figure [3](#jah33801-fig-0003){ref-type="fig"}A shows activation sequences and V1 to V3 recordings for 4 different \[K^+^\]~o~ (5.4, 7.5, 10.0, and 10.5 mmol/L) in the presence and absence of fibrosis at the RVOT. Conduction at the RVOT was significantly altered at 65% fibrosis, with changes in the activation sequence that promoted the appearance of late and fractionated potentials on V1 to V3. There was a progressive slowing of conduction with increasing \[K^+^\]~o~. At 5.4 mmol/L, CV at the RVOT in the absence of fibrosis was 97.89  versus 60.81 cm/s when fibrosis was included. In hyperkalemic conditions (\[K^+^\]~o~=10.0 mmol/L), CV was 57.53 cm/s at baseline versus 28.66 cm/s in the fibrotic RVOT. Increasing \[K^+^\]~o~ to 10.5 mmol/L reduced CV to 47.22 cm/s at baseline, but produced unexcitability and propagation failure in the fibrotic RVOT. A similar progression was also apparent on the V1, V2, and V3 recordings for each \[K^+^\]~o~ and normal/fibrotic state. Notable changes occurred on leads V1 and V2, where there was delayed activation at the RVOT, which prolonged the QRS interval proportionately. Moreover, the ST‐segment elevated and gradually fussed with the T wave as the \[K^+^\]~o~ increased. In the absence of fibrosis, at \[K^+^\]~o~=10.0 mmol/L, the model reproduced the characteristic features of hyperkalemia in patients with healthy RVOT. In contrast, in the fibrotic case, conduction slowing or block promoted ST‐segment elevation on V1 and V2, consistent with the classical BrS descriptors. In Figure [3](#jah33801-fig-0003){ref-type="fig"}B, the corresponding action potential duration (APD) maps show a progressive global decrease in the APD as \[K^+^\]~o~ is increased. As illustrated also by the action potential recordings at specific locations, fibrosis intensified both the APD shortening and the activation delay at the RVOT and its immediate vicinity.

![Computer simulations testing the role of fibrosis of the right ventricular outflow tract (RVOT) at different levels of hyperkalemia. A, Activation isochrones maps of the anterior wall with healthy (upper) and fibrotic RVOT (bottom), under basal conditions with extracellular potassium concentration (\[K^+^\]~o~)=5.4 mmol/L and hyperkalemic conditions with \[K^+^\]~o~=7.5 mmol/L, \[K^+^\]~o~=10.0 mmol/L, and \[K^+^\]~o~=10.5 mmol/L. Pseudo‐ECGs of V1, V2, and V3 leads are shown in each case. **B**, Action potential duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case.](JAH3-8-e010115-g003){#jah33801-fig-0003}

Role of I~to~ {#jah33801-sec-0017}
-------------

Previous evidence has implicated the epicardial‐to‐endocardial I~to~ gradient within the right ventricle in the pathogenesis and phenotypic expression of BrS.[2](#jah33801-bib-0002){ref-type="ref"} We therefore conducted additional simulations to test the consequences of combining hyperkalemia with increased epicardial I~to~ gradient at the RVOT in the presence and absence of fibrosis. The gradient was established by increasing the baseline value of the epicardial band to 0.30, 0.70, and 1.50 mS/μF, while leaving the endocardium at the basal level (0.08 mS/μF). In Figure [4](#jah33801-fig-0004){ref-type="fig"}A, under basal \[K^+^\]~o~ conditions, we had to increase the maximal I~to~ conductance up to 1.50 mS/μF, to enable BrPh, a value that is characteristic of BrS modeling.[4](#jah33801-bib-0004){ref-type="ref"} Increasing I~to~ produced a progressively exaggerated action potential notch (arrow) at the RVOT while the rest of the tissue was undergoing initial depolarization during the plateau (Figure [4](#jah33801-fig-0004){ref-type="fig"}B). On the electrograms, these events coincided with ST‐segment elevation (Figure [4](#jah33801-fig-0004){ref-type="fig"}A).

![Computer simulations testing the role of incremental transient outward current (I~to~) conductance. **A**, Activation isochrones maps of the anterior right ventricular outflow tract (RVOT) wall with increasing the maximal conductance of I~to~ in the RVOT epicardium, from its basal level to a characteristic value in BrS modeling (from 0.08 to 1.50 mS/μF, showing 0.30 and 0.70 mS/μF), under severe hyperkalemia (extracellular potassium concentration \[K^+^\]~o~=10.5 mmol/L). Pseudo‐ECGs of V1, V2, and V3 leads are shown in each case. **B**, Action potential duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case. BrS indicates Brugada syndrome.](JAH3-8-e010115-g004){#jah33801-fig-0004}

As illustrated in Figure [5](#jah33801-fig-0005){ref-type="fig"}, the combined effects of fibrosis, elevated \[K^+^\]~o~‐induced membrane depolarization leading to reduced excitability, and increased I~to~ density greatly facilitated the appearance of BrPh on leads V1 to V2. In Figure [5](#jah33801-fig-0005){ref-type="fig"}A, a BrPh pattern was already evident on V1 and V2 at 55% fibrosis even when the epicardial I~to~ was at baseline (0.08 mS/μF). The effect was even greater when fibrosis at the RVOT was increased to 75%. Here, ST‐segment elevation occurred at 10 mmol/L \[K^+^\]~o~ because of extreme conduction delay at the RVOT (Figure [5](#jah33801-fig-0005){ref-type="fig"}B).

![Computer simulations testing the role of incremental fibrosis, transient outward current (I~to~) conductance, and extracellular potassium concentration (\[K^+^\]~o~) conditions. **A**, Activation isochrones maps of the anterior right ventricular outflow tract (RVOT) wall with different degrees of fibrosis (55, 65, and 75%), at baseline and severe \[K^+^\]~o~ concentrations (5.4 and 10.5 mmol/L, respectively), combined with 2 values of maximal conductance of I~to~: basal (0.08 mS/μF) or increased (0.50 mS/μF). Pseudo‐ECGs of V1, V2, and V3 leads are shown in each case. **B**, Action potential duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case.](JAH3-8-e010115-g005){#jah33801-fig-0005}

In additional simulations, we assessed the effects of fibrosis and I~to~ current gradient on the entire ventricular wall. The effects were similar to those observed when such changes were only applied to the RVOT. The relative increase in I~to~ over the entire epicardial surface with respect to the endocardium simulated characteristics of the Brugada pattern (Figure [6](#jah33801-fig-0006){ref-type="fig"}). At baseline, the I~to~ gradient caused an increase in the duration of the epicardial action potential by increasing the transmembrane potassium outflow during the whole plateau phase. This slightly elevated the ST segment and decreased the T‐wave amplitude, even depressing the T wave on V3. However, the \[K^+^\]~o~ increase also depolarized the membrane potential and reduced the availability of the sodium channels. Consequently, conduction velocity was reduced and the APD was abbreviated, with the appearance of regions of activation failure. Fibrosis throughout the ventricular surface slowed activation and wavefront propagation (Figure [7](#jah33801-fig-0007){ref-type="fig"}), prolonging the QRS and delaying T‐wave activation more than when fibrosis was present in the RVOT. When the \[K^+^\]~o~ was raised to a pathological threshold, conduction slowed further with propagation failure in areas with less excitable cardiac tissue, including the RVOT and its surroundings. ST‐segment elevation did not occur under these conditions because of the conduction slowing generated.

![Computer simulations testing the role of gradient of I~to~ conductance over the entire epicardial surface at different levels of extracellular potassium concentration (\[K^+^\]~o~). **A**, Activation isochrones maps with I~to~ maximal conductance in the whole epicardium to a characteristic value in BrS modeling (1.50 mS/μF), under basal conditions (\[K^+^\]~o~=5.4 mmol/L) and hyperkalemic conditions (\[K^+^\]~o~=10.5 mmol/L). Pseudo‐ECGs of V1, V2, and V3 leads are shown in each case. **B**, Action potential duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case. BrS indicates Brugada syndrome; I~to~, transient outward current.](JAH3-8-e010115-g006){#jah33801-fig-0006}

![Computer simulations testing the role of fibrosis over the entire epicardial surface at different levels of extracellular potassium concentration (\[K^+^\]~o~). **A**, Activation isochrones maps with fibrosis in the whole (65%), under basal conditions (\[K^+^\]~o~=5.4 mmol/L) and hyperkalemic conditions (\[K^+^\]~o~=10.5 mmol/L). Pseudo‐ECGs of V1, V2, and V3 leads are shown in each case. **B**, Action potential duration (APD) maps and corresponding action potential signals of sites a, b, and c are shown in each case.](JAH3-8-e010115-g007){#jah33801-fig-0007}

Proarrhythmic Risk of BrPh Pattern Attributed to Hyperkalemia {#jah33801-sec-0018}
-------------------------------------------------------------

The foregoing simulations provide insight into the mechanism underlying the observed predisposition of BrPh patients to malignant arrhythmias, as illustrated in the following clinical example: Patient 5 (Table [1](#jah33801-tbl-0001){ref-type="table"}) arrived at the emergency department after suffering an out‐of‐hospital sudden death episode, showing complex ventricular rhythm with wide QRS. An intravenous bolus of adenosine (12 mg) transiently slowed the rhythm and normalized the QRS complex duration. When the adenosine effect faded, the ventricular rhythm accelerated and resumed with progressive QRS widening (Figure [8](#jah33801-fig-0008){ref-type="fig"}A through [8](#jah33801-fig-0008){ref-type="fig"}C). The patient had a low conscience level, was tachypneic, and had a blood pressure of 100/55 mm Hg. Urgent blood analyses showed serum K^+^ levels of 9.1 mmol/L. He was treated with intravenous fluids (2 L of glucosaline), intravenous sodium bicarbonate, 1 g of intravenous calcium chloride, and insulin. One hour later, the K^+^ level was 8.1 mmol/L and the ECG showed a BrPh pattern (Figure [8](#jah33801-fig-0008){ref-type="fig"}C). The observed changes were consistent with adenosine activation of *I* ~K,Ado~ channels, which, by increasing K^+^ conductance, hyperpolarized the cell membrane, abbreviated the APD and the refractory period, and inhibited spontaneous pacemaker discharge, leading to significant QRS narrowing and transient sinus arrest.[27](#jah33801-bib-0027){ref-type="ref"} This finding was further confirmed by our computer simulations. In Figure [9](#jah33801-fig-0009){ref-type="fig"}, we used a fibrotic RVOT with hyperkalemic conditions at \[K^+^\]~o~=10.0 mmol/L. A burst stimulus train with an extra stimulus at 400 ms increased electrogram fractionation and caused unidirectional block that allowed stable reentry formation at the RVOT.

![Wide complex tachycardia response to adenosine in a patient with severe hyperkalemia. **A**, Wide complex tachycardia upon arrival (serum potassium \[K\]=9.1 mmol/L). **B**, ECG recording during peak adenosine effect showing sinus arrest and significant QRS narrowing, followed by accelerated ventricular rhythm with progressive QRS widening later after disappearance of the adenosine effect. **C**, One hour later, after the initial treatment of hyperkalemia (\[K\] = 8.1 mmol/L).](JAH3-8-e010115-g008){#jah33801-fig-0008}

![Monomorphic ventricular tachycardia induction during burst stimulation train followed by an extrastimuli at 400 ms allowed a stable reentry formation at the right ventricular outflow tract (RVOT) fibrotic site in a model with hyperkalemic conditions and extracellular potassium concentration of 10.0 mmol/L.](JAH3-8-e010115-g009){#jah33801-fig-0009}

Discussion {#jah33801-sec-0019}
==========

The main findings of this study are as follows: 1. In patients with severe hyperkalemia resulting from a critical medical condition, the presence of a BrS phenotype is associated with a high prevalence of malignant arrhythmias and all‐cause mortality. 2. In surviving patients, the characteristic Brugada ECG changes are transient and disappear when the serum K^+^ levels normalize. 3. In patients with BrS, hyperkalemia may elicit the typical BrS ECG manifestations. 4. Higher serum K^+^ levels and male sex were independent predictors for the presence of BrPh ECG in patients with severe hyperkalemia. 5. As shown by the response to adenosine infusion and computer simulations, ECG manifestations of systemic hyperkalemia are a consequence of the depolarized resting membrane potential and reduced sodium‐channel availability for action potential activation, which results in delayed and heterogeneous conduction, or block, particularly in the presence of fibrosis at the RVOT.

Systemic Hyperkalemia Causing BrPh {#jah33801-sec-0020}
----------------------------------

Systemic hyperkalemia is most frequently found in patients with chronic and acute renal failure and/or concomitant treatments with nephrotoxic medications or K‐sparing drugs. The classical electrocardiographic manifestations of hyperkalemia were first documented in the early 1950s by the presence of peaked T waves, shortened QT interval, lengthening of the PR interval, loss of *P* waves, and widening of the QRS complex.[28](#jah33801-bib-0028){ref-type="ref"} Moreover, Levine et al also described the presence of the "dialyzable" current of injury resembling acute myocardial infarction or pericarditis.[29](#jah33801-bib-0029){ref-type="ref"} However, Littmann et al reported the first consecutive series that recognized the similarities between the classic BrS ECG manifestations and those occasionally shown in the context of severe hyperkalemia.[11](#jah33801-bib-0011){ref-type="ref"} In agreement with this and other studies,[10](#jah33801-bib-0010){ref-type="ref"}, [11](#jah33801-bib-0011){ref-type="ref"}, [30](#jah33801-bib-0030){ref-type="ref"} we found that BrPh was most likely present in critically ill male patients with severe decompensation of their renal function and/or malignancies, with high mortality mostly related to their underlying clinical condition. In addition, we found that compared with hyperkalemic patients without Brugada ECG, the BrPh patients presented in males with higher serum K^+^ values (1 mmol/L higher on average). Moreover, lower pH was also strongly related to the development of BrPh. These data, together with the presence of other outcome predictors, such as younger age, lower hypertension prevalence, and lesser chronic renal disease, further confirm the importance of acute increments in K^+^ levels, which might be underestimated in terminal renal failure patients.[31](#jah33801-bib-0031){ref-type="ref"} Given that the density of the strong inward rectifying K^+^ current, I~K1~, which maintains the resting membrane potential of the ventricular myocyte, is strictly controlled by \[K^+^\]~o~, acute increases in \[K^+^\]~o~, however transient, may place such patients at risk of malignant arrhythmias.[32](#jah33801-bib-0032){ref-type="ref"} The findings of our multivariant analyses further support the predominant role of male sex and higher hyperkalemia levels, together with the role for the acid group presence on the reduction of channel conductance favoring the occurrence of malignant ventricular arrhythmias, as shown in our simulations.[33](#jah33801-bib-0033){ref-type="ref"}

We compared the clinical manifestations, ECG, and outcomes (malignant arrhythmias and mortality) of BrPh patients with those of severe hyperkalemic patients (K^+^ ≥6.5 mmol/L) without BrS phenotype. Overall, patients with the BrPh ECG had a grave prognosis with a short‐ to mid‐term fatality rate of 51% not only related to the baseline clinical disease, but also to the clinical impact of malignant ventricular arrhythmias. Moreover, although patients presenting with BrPh had a higher likelihood of developing malignant arrhythmias than non‐BrPh patients (43% versus 25%), in‐hospital mortality was similar because of the poor clinical status in both groups. Junttila et al [34](#jah33801-bib-0034){ref-type="ref"} reported on a series of patients with typical Brugada‐type ECG during an acute medical event (including 5 patients with electrolyte imbalance), where 51% presented malignant arrhythmias and 38% developed sudden cardiac arrest. Unfortunately, in that report, only a minority of patients had a confirmed BrS genetic test. In our cohort of surviving patients, the characteristic BrS ECG changes disappeared when K^+^ levels normalized. We attempted to perform a flecainide test after serum K^+^ levels became normal and found a BrS typical ECG that was unmasked by the hyperkalemic state. Postema et al[35](#jah33801-bib-0035){ref-type="ref"} previously reported a similar case of diabetic ketoacidosis with concomitant hyperkalemia that uncovered a typical BrS.

We compared the ECG of hyperkalemic patients and found that patients showing a BrPh had a wider QRS, and frequently presented abnormal QRS axis and a greater T‐wave height compared with non‐BrPh hyperkalemic patients (Table [3](#jah33801-tbl-0003){ref-type="table"}). This contrasted with patients with inheritable BrS that usually have mildly widened QRS complexes, but normal QRS axes on an otherwise normal ECG.[11](#jah33801-bib-0011){ref-type="ref"}, [36](#jah33801-bib-0036){ref-type="ref"} Thus, the presence of moderate‐to‐severe hyperkalemia, especially with a Brugada ECG pattern or atypical ST‐segment elevation on the right precordial leads without BrS, should be aggressively treated and considered a risk factor for development of life‐threatening cardiac arrhythmias. This is in agreement with previous studies showing that presence of an aVR sign and/or ST‐segment elevation on the right precordial leads pattern reflects more right ventricular conduction delay and electrical heterogeneity, increasing the risk for developing arrhythmic events.[18](#jah33801-bib-0018){ref-type="ref"}, [19](#jah33801-bib-0019){ref-type="ref"}

Mechanism of Proarrhythmic Risk of BrPh Pattern Attributed to Hyperkalemia {#jah33801-sec-0021}
--------------------------------------------------------------------------

To our knowledge, the relationship between hyperkalemia and the BrS ECG manifestations had not yet been systematically investigated. Together, the clinical results and computer simulations presented above provide mechanistic insight into the manifestation of electrolytic dysregulation causing Brugada phenotype. Even in the absence of genetic disease (eg, inheritable SCN5A mutations), delays in ventricular activation, and propagation failure at the RVOT, magnified by the presence of hyperkalemia and, possibly, low acid base state, promote the required electrophysiological changes, including APD shortening, membrane depolarization, and reduced sodium‐channel availability, which enable the manifestation of BrPh ECG, an effect that is magnified by RVOT fibrosis. Introduction of fibrotic tissue reduced the excitability of the RVOT and slowed CV, leading to a ST‐segment elevation on V1 and V2 leads, creating the substrate for inducibility of malignant arrhythmias. In agreement with previous clinical reports, computer simulations showed that programmed stimulation caused electrogram fractionation and unidirectional block to initiate stable reentry formation without the need of an extrasytole.[8](#jah33801-bib-0008){ref-type="ref"} Unexcitability attributed to the high concentration of potassium and its propensity to the generation of arrhythmias agrees with recent reports.[12](#jah33801-bib-0012){ref-type="ref"} These results are supported by simulations by other groups showing that activation delay and right ventricular excitation failure attributed to current‐load mismatch secondary to decrease in calcium current or increase in I~to~ can cause BrS.[16](#jah33801-bib-0016){ref-type="ref"}, [17](#jah33801-bib-0017){ref-type="ref"} Similar mechanisms could be responsible for other types of BrPh, with low availability of sodium channels given that it occurs during hypothermia or acidosis in ischemic regions.

The relative increase in I~to~ density at the RVOT reduced the need for slow conduction caused by hyperkalemia and resulted in spatial gradients of membrane voltage giving rise to the typical ST‐segment elevation found in BrPh. In agreement with BrS, the strong sex‐related predominance found in the BrPh indirectly supports the prominence of the transient outward current‐mediated action potential notch in the right ventricular epicardium of males.[37](#jah33801-bib-0037){ref-type="ref"} Moreover, the combination of abnormal repolarization and abnormal conduction not only explains the phenotypic manifestation of the BrPh, but also its clinical arrhythmic outcomes in the form of sustained ventricular reentrant patterns. On one hand, the presence of steep repolarization gradients causes asymmetry in excitability that gives rise to unidirectional block. On the other, slow conduction shortens the wavelength of the reentrant AP facilitating reentrant stabilization (Figures [8](#jah33801-fig-0008){ref-type="fig"} and [9](#jah33801-fig-0009){ref-type="fig"}). Therefore, severe hyperkalemia leading to inactivation of the sodium channel in conjunction with presence of subtle structural abnormalities of the FVOT were responsible for the BrPh manifestation and reentrant arrhythmia occurrence in this setting.

Limitations {#jah33801-sec-0022}
-----------

The observational and retrospective nature of the study prevented clinical data collections (ie, acid group value) and reduced the number of available ECGs. Although the computer simulations support the theory that RVOT has a major role producing Brugada patterns, further clinical data (histological and image data) and cellular studies are necessary to accurately define the substrate of this clinical entity in this environment.[15](#jah33801-bib-0015){ref-type="ref"}, [38](#jah33801-bib-0038){ref-type="ref"} For example, imaging (eg, magnetic resonance imaging) data in patients presenting with a BrPh ECG could have shown enhanced fibrosis in the RVOT, as predicted by the modeling results. However, magnetic resonance imaging was nearly impossible in our study because of the fact that many of the patients were critically ill and had a very poor outcome, which substantially limited the number of patients available to study.

Conclusion {#jah33801-sec-0023}
==========

This report adds to our understanding of the electrocardiographic features of hyperkalemic BrPh patients. In patients with severe hyperkalemia attributed to critical medical conditions, a BrPh ECG is associated with a high prevalence of malignant arrhythmias and high all‐cause mortality. BrPh ECG manifestations in patients with hyperkalemia are attributed to depolarized resting membrane potential and reduced availability of inward sodium channels. Although I~to~ elevation contributes, it is not essential to generate the hyperkalemic Brugada phenotype.
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